Kara Griffith
Family · Youngstown, OHNPI 1629718242
Payments from drug & device makers
Across 133 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$580
- United Therapeutics Corporation$424
- GSK$312
- Harmony Biosciences LLC$244
- Regeneron Healthcare Solutions, Inc.$233
- Jazz Pharmaceuticals Inc.$193
- plus $742 from 13 others
What the payments were for
- Food & beverage$2,66798%
- Education$602%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $580 |
| United Therapeutics Corporation | 11 | $424 |
| GSK | 23 | $312 |
| Harmony Biosciences LLC | 16 | $244 |
| Regeneron Healthcare Solutions, Inc. | 11 | $233 |
| Jazz Pharmaceuticals Inc. | 5 | $193 |
| Boehringer Ingelheim | 8 | $155 |
| Amgen | 7 | $153 |
| Mylan Specialty L.p. | 6 | $124 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Grifols USA, LLC | 2 | $39 |
| Merck | 2 | $36 |
| Actelion Pharmaceuticals US, Inc. | 2 | $34 |
| Inogen, Inc. | 2 | $33 |
| Sanofi | 1 | $32 |
| Baxter Healthcare | 2 | $30 |
| Novartis | 1 | $30 |
| Electromed, Inc. | 1 | $18 |
| Bayer | 1 | $16 |
How this compares
$2,727 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $47,493 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $29,759 |
| EliquisApixaban | 12 | $11,261 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $7,096 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,820 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $5,236 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 73 | $1,766 |
| Montelukast Sodium | 47 | $529 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $312 | $61,41093 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $580 | $34,99550 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.
Other family in Youngstown
- Andrea SvobodaYoungstown$91K
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.